Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
Healthy Volunteers
NCT07262333

A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency

Led by Beijing Continent Pharmaceutical Co, Ltd. · Updated on 2026-04-06

56

Participants Needed

1

Research Sites

26 weeks

Total Duration

On this page

Sponsors

B

Beijing Continent Pharmaceutical Co, Ltd.

Lead Sponsor

U

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborating Sponsor

AI-Summary

What this Trial Is About

Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally. The applicant has completed the preliminary Phase I and Phase II clinical trials. The results showed that Hydronidone is a safe and effective drug for treating liver fibrosis in chronic hepatitis B, and it has good safety and tolerability. Based on the preliminary clinical research, a special population study has been initiated. The aim is to investigate the pharmacokinetic differences and safety of honginone capsules in patients with renal insufficiency and healthy subjects, in order to provide a basis for the clinical medication of patients with renal dysfunction.

CONDITIONS

Official Title

A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency

Who Can Participate

Age: 18Years - 70Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy Chinese adults aged 18 to 70 years with estimated glomerular filtration rate (eGFR) between 90 and 130 mL/min
  • Patients aged 18 to 70 years diagnosed with renal dysfunction classified as mild (eGFR 60-89 mL/min), moderate (eGFR 30-59 mL/min), or severe (eGFR 15-29 mL/min)
  • Male participants weighing at least 50 kg and female participants weighing at least 45 kg, with body mass index (BMI) between 18 and 28
  • Agree to abstain from smoking, alcohol, fruit juices, caffeine, and tea from 24 hours before until the end of the trial
  • Ability to understand and voluntarily sign informed consent and comply with study requirements
Not Eligible

You will not qualify if you...

  • Participation in any clinical trial within 3 months prior to the study
  • Any disease affecting drug safety or processing including heart, liver, digestive, immune or respiratory diseases, excluding renal insufficiency
  • History of allergies to two or more drugs, foods, or lactose intolerance
  • Use of drugs that induce or inhibit liver enzymes within 28 days before dosing
  • Use of drugs affecting SULT and UGT enzymes within 7 days prior to dosing
  • History of fainting or intolerance to blood draws
  • Excessive consumption of caffeine or tea, or intake of foods or drinks that affect liver metabolism within 24 hours before dosing
  • Blood donation or large blood loss within 3 months before dosing or planned during the study
  • Acute illness during screening or before dosing
  • Pregnancy, breastfeeding, or unwillingness to use contraception during and after the study
  • Recent or planned surgery affecting drug metabolism
  • History of drug abuse
  • Smoking more than 5 cigarettes daily within 14 days before screening or inability to stop tobacco use during the trial
  • Clinically significant abnormalities in physical exams, ECG, lab tests excluding those due to renal insufficiency
  • Positive tests for nicotine, alcohol, drugs, hepatitis B, hepatitis C, syphilis, or HIV
  • Any condition affecting informed consent or study compliance as determined by researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Hubei, Wuhan, China

Actively Recruiting

Loading map...

Research Team

L

Ling Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here